Press coverage about Ritter Pharmaceuticals (NASDAQ:RTTR) has trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.5168175118178 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com)
- Volatile Stock Characteristics – Ritter Pharmaceuticals, Inc., (NASDAQ: RTTR) – Stock Watch (stocksnewstimes.com)
- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) – Analysts’ Recommendation in Spotlight – Nasdaq Journal (press release) (nasdaqjournal.com)
- Eye-Catching Hot Stocks – Ritter Pharmaceuticals, Inc., (NASDAQ: RTTR) – Stock Watch (stocksnewstimes.com)
- Who Are Ritter Pharmaceuticals Inc’s (RTTR) Major Shareholders? (finance.yahoo.com)
Several equities analysts recently issued reports on RTTR shares. Roth Capital set a $2.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 16th. Finally, HC Wainwright reduced their price objective on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research note on Monday, October 23rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Ritter Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $2.92.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). sell-side analysts predict that Ritter Pharmaceuticals will post -0.66 earnings per share for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.